Novo Nordisk, Inc. is a major pharmaceutical company based in New Jersey. Its filings show it lobbies Congress mainly on budget and health issues, especially laws and funding related to obesity treatments and anti-obesity medications, including the Treat and Reduce Obesity Act. It has reported $210,000 across four filings and used Holland & Knight LLP for lobbying.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
JORDAN BROSSI
The latest disclosures for this client.
HOLLAND & KNIGHT LLP
Q1HOLLAND & KNIGHT LLP
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
HOLLAND & KNIGHT LLP
MIRANDA FRANCO
HOLLAND & KNIGHT LLP
SHAWNA FRANCIS WATLEY
HOLLAND & KNIGHT LLP
ED PERLMUTTER
HOLLAND & KNIGHT LLP
HOLLAND & KNIGHT LLP
Q3HOLLAND & KNIGHT LLP
Q2HOLLAND & KNIGHT LLP
Q1